<DOC>
	<DOC>NCT01389206</DOC>
	<brief_summary>This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III &amp; IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II &amp; FC I patients.</brief_summary>
	<brief_title>Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1. Male and female adults (&gt;/= 18 years of age) 2. Documented diagnosis of pulmonary arterial hypertension (PAH) (all of the following): Right Heart Catheterization (RHC) demonstrating mean Pulmonary Arterial Pressure (mPAP) &gt; 25mm Hg and Pulmonary Capillary Wedge Pressure (PCWP) &lt;= 15 and PVR &gt; 3 Forced Expiratory Volume in the first second (FEV1) &gt; 50% predicted normal Ventilation/Perfusion (V/Q) and/or Computerized Tomography (CT) scan excluding the thromboembolic etiology 3. Diagnosis of PAH &lt; 3 years 4. Need for PAH specific treatment 5. Desire to participate and signs an Informed Consent. Any of the criteria below: Poor mental function, drug or substance (e.g., alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study Prior participation in this program Patients with Pulmonary Hypertension (PH) classified as group 2 5 Updated Clinical Classification of PH (5th World Symposium on PH Modified Classification of PH).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>